KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elanco Animal Health (ELAN) Short-term Investments (2018 - 2020)

Historic Short-term Investments for Elanco Animal Health (ELAN) over the last 3 years, with Q4 2020 value amounting to $11.0 million.

  • Elanco Animal Health's Short-term Investments fell 90.09% to $11.0 million in Q4 2020 from the same period last year, while for Dec 2020 it was $11.0 million, marking a year-over-year decrease of 90.09%. This contributed to the annual value of $11.0 million for FY2020, which is 90.09% down from last year.
  • As of Q4 2020, Elanco Animal Health's Short-term Investments stood at $11.0 million, which was down 90.09% from $11.0 million recorded in Q3 2020.
  • In the past 5 years, Elanco Animal Health's Short-term Investments ranged from a high of $634.9 million in Q3 2018 and a low of $11.0 million during Q1 2020
  • Moreover, its 3-year median value for Short-term Investments was $11.1 million (2019), whereas its average is $94.4 million.
  • In the last 5 years, Elanco Animal Health's Short-term Investments tumbled by 9825.17% in 2019 and then plummeted by 90.09% in 2020.
  • Over the past 3 years, Elanco Animal Health's Short-term Investments (Quarter) stood at $202.7 million in 2018, then crashed by 94.52% to $11.1 million in 2019, then fell by 0.9% to $11.0 million in 2020.
  • Its Short-term Investments was $11.0 million in Q4 2020, compared to $11.0 million in Q3 2020 and $11.0 million in Q2 2020.